Abstract
Get full access to this article
View all access options for this article.
References
1.
Miller
JL
. Celecoxib approved as NSAID with some concessions on class warning . Am J Health Syst Pharm
1999 ;56 :403 .
2.
Hawkey
CJ
. COX-2 inhibitors . Lancet
1999 ;353 :307 –14 .
3.Package insert . Celebrex (celecoxib) . Chicago : GDSearle , May 21, 1999 .
4.
Gordon
J
Rojas-Fernandez
C
Rockwood
K
. Practical solutions to polypharmacy problems in the elderly . Can J Diag
1998 ;15 :78 –90 .
5.
Sotaniemi
EA
Arranto
AJ
Pelkonen
O
Pasanen
M
. Age and cytochrome P450–linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions . Clin Pharmacol Ther
1997 ;61 : 331 –9 .
6.
Mungall
DR
Ludden
TM
Marshall
J
Hawkins
DW
Talbert
RL
Crawford
MH
. Population pharmacokinetics of racemic warfarin in adult patients . J Pharmacokinet Biopharm
1985 ;13 :213 –27 .
7.
Naranjo
CA
Busto
U
Sellers
EM
Sandor
P
Ruiz
I
Roberts
EA
A method for estimating the probability of adverse drug reactions . Clin Pharmacol Ther
1981 ;30 :239 –45 .
8.FDA MedWatch program. Food and Drug Administration . [cited 1999 Jul 21] Available from URL: http://www.fda.gov/medwatch/safety/1999/celebr.htm.
9.
Kaplan-Machlis
B
Klostermeyer
BS
. The cyclooxygenase-2 inhibitors: Safety and effectiveness . Ann Pharmacother
1999 ;33 :979 –88 .